Disclaimer: This article has been developed and funded by Daiichi Sankyo. Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market ...

AZ and Daiichi Sankyo have said that NICE's decision on ... than the end-of-life modifier it replaced. Patient advocacy group Breast Cancer Now said the failure to reach an agreement – despite ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...

Daiichi Sankyo and AstraZeneca are committed to collaborating with patient advocacy groups to provide reliable information and resources. It is crucial that everyone has access to potentially life ...

The advocacy group Patients for Affordable Drugs ... Since its launch in 2019, its manufacturers, Daiichi Sankyo and AstraZeneca, have raised the price of Enhertu eight times, with the latest ...

Daiichi Sankyo Co. said on Friday it submitted its mRNA-based COVID-19 vaccine for regulatory approval in Japan. Approval would give Japan a home-grown mRNA vaccine of the type that have made up ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. December 24 ...

A health ministry panel of experts on July 31 endorsed the plan for Daiichi Sankyo Co. to begin producing and distributing the vaccine, which creates immunity for the conventional strain of the virus.

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...